Premium
“LONG‐TERM” SURVIVAL IN LIGHT‐CHAIN MYELOMA WITH DIALYSIS THERAPY ALONE
Author(s) -
BOYCE N. W.,
HOLDSWORTH S. R.,
THOMSON N. M.,
ATKINS R. C.
Publication year - 1984
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1984.tb05027.x
Subject(s) - medicine , multiple myeloma , dialysis therapy , uremia , dialysis , continuous ambulatory peritoneal dialysis , peritoneal dialysis , chemotherapy , hemodialysis , intensive care medicine , natural history , ambulatory , surgery , oncology
Abstract: We report a case of a 59 year old woman who presented in end‐stage renal failure with lambda (A) light‐chain myeloma (LLCM). Despite a large tumour burden, and refusal to accept cytotoxic chemotherapy, she was commenced on continuous ambulatory peritoneal dialysis (CAPO). With dialysis therapy alone she has shown considerable hematological improvement and remains well 18 months after diagnosis. The extremely poor prognosis attributed to light‐chain myeloma is largely due to death from uremia. As the natural history of this disease in patients offered dialysis therapy is unknown, dialysis should not automatically be withheld from patients with LLCM.